PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcresnotesBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleBMC Research Notesjournal front page
 
BMC Res Notes. 2012; 5: 694.
Published online Dec 24, 2012. doi:  10.1186/1756-0500-5-694
PMCID: PMC3532378
Expression of antigen tf and galectin-3 in fibroadenoma
Itandehui Belem Gallegos,1 Eduardo Pérez-Campos,2 Margarito Martinez,2 Miguel Ángel Mayoral,1 Laura Pérez,1 Sergio Aguilar,1 Edgar Zenteno,3 Maria del Socorro Pina,1 and Pedro Hernándezcorresponding author1
1Centro de Investigaciones en Ciencias Medicas y Biológicas Facultad de Medicina, Universidad Autónoma Benito Juárez de Oaxaca, 68020, Oaxaca, Mexico
2Unidad de Investigación en Bioquímica, Instituto Tecnológico de Oaxaca, Oaxaca, Mexico
3Laboratorio de Inmunología, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico, 04510, Mexico
corresponding authorCorresponding author.
Itandehui Belem Gallegos: ITANBEL/at/hotmail.com; Eduardo Pérez-Campos: perezcampos123/at/yahoo.es; Margarito Martinez: martinezcu9/at/hotmail.com; Miguel Ángel Mayoral: mianmayo/at/yahoo.com; Laura Pérez: laurapcm/at/prodigy.net.mx; Sergio Aguilar: sar_cinvestav/at/hotmail.com; Edgar Zenteno: ezenteno/at/unam.mx; Maria del Socorro Pina: socopina12/at/hotmail.com; Pedro Hernández: fuegoblanco136/at/yahoo.com.mx
Received August 30, 2012; Accepted December 18, 2012.
Background
Fibroadenomas are benign human breast tumors, characterized by proliferation of epithelial and stromal components of the terminal ductal unit. They may grow, regress or remain unchanged, as the hormonal environment of the patient changes. Expression of antigen TF in mucin or mucin-type glycoproteins and of galectin-3 seems to contribute to proliferation and transformations events; their expression has been reported in ductal breast cancer and in aggressive tumors.
Findings
Lectin histochemistry, immunohistochemistry, and immunofluorescence were used to examine the expression and distribution of antigen TF and galectin-3. We used lectins from Arachis hypogaea, Artocarpus integrifolia, and Amaranthus lecuocarpus to evaluate TF expression and a monoclonal antibody to evaluate galectin-3 expression. We used paraffin-embedded blocks from 10 breast tissues diagnosed with fibroadenoma and as control 10 healthy tissue samples. Histochemical and immunofluorescence analysis showed positive expression of galectin-3 in fibroadenoma tissue, mainly in stroma, weak interaction in ducts was observed; whereas, in healthy tissue samples the staining was also weak in ducts. Lectins from A. leucocarpus and A. integrifolia specificaly recognized ducts in healthy breast samples, whereas the lectin from A. hypogaea recognized ducts and stroma. In fibroadenoma tissue, the lectins from A. integrifolia, A. Hypogaea, and A. leucocarpus recognized mainly ducts.
Conclusions
Our results suggest that expression of antigen TF and galectin-3 seems to participate in fibroadenoma development.
Keywords: Antigen TF, Galectin-3, Fibroadenoma, Breast cancer, Plant lectins
Fibroadenomas are benign breast tumors commonly found in young women. Fibroadenoma is a biphasic lesion of the breast characterized by proliferation of both epithelial and stromal components of the terminal ductal unit. Proliferation of stromal cells is commonly considered the primary event in the development of a fibroadenoma, followed by secondary proliferation of epithelial cells [1]. Most fibroadenomas are considered to be the result of hyperplastic processes involving connective tissue of lobular units [2]. Fibroadenomas’ development is heterogeneous, since they may grow, regress, or remain unchanged as the hormonal environment ofthe patient changes, but most stop growing after reaching 2 to 3 cm in diameter [3], moreover, with aging, the stroma becomes less cellular and increases its hyalinization [4]. Occurrence in young women and sclerotic involution in the elderly suggest a hormonal responsiveness of fibroadenomas [1].
O-glycosylation plays an important role in the biological activity of glycoproteins involved in controlling cell differentiation [5,6]. Alterations in glycosylation of cell membrane glycocongugates in neoplastic lesions from a variety of organs, including lung, stomach, ovary, skin and endometrium, have been reported [7,8]. Abnormal O-glycosylation, especially in mucin and mucin type glyproteins, results in exposure of the peptide core, as well as in the exposure of the normally cryptic core TF (Galβ1-3GalNAcα1-O-Ser/Thr) antigen [9], which is distributed discontinuously along the peptide backbone, and premature sialylation can occur leading to formation of antigens related to cancer progression [10].
Lectins are proteins that recognize carbohydrates or precipitate glycoconjugates and they are important tools for oligosaccharide characterization as well as for isolation of cellular populations [11]. Galectin-3 is a 31 kDa protein member of the beta-galactoside-binding proteins; it is an intracellular and extracellular lectin that interacts with intracellular glycoproteins, cell surface molecules, and extracellular matrix proteins. Galectin-3 is expressed widely in epithelial and immune cells and its expression is correlated with cancer aggressiveness and metastasis [12]. The aim of this study was to determine, by histochemsitry, the over-expression of antigen TF and galectin-3 in fibroadenoma and healthy breast tissues, using specific lectins for antigen TF and anti-galectin-3 antibody, to understand better the potential role of O-glycosylation in fibroadenomas’ progression.
Reagents
Biotynilated lectins from Arachis hypogaea and Artocarpus integrifolia were obtained from Vector Laboratories (Burlingame, CA USA). Lectin from Amaranthus leucocarpus (ALL) was purified by affinity chromatography using a column containing stroma from human O-desialylated erythrocytes entrapped in Sephadex G-25 (Upssula Sweden), as described previously [13]. ALL was labeled with the N-hydroxisuccinimide ester of biotin (Bio-Rad Inc., Richmond, CA, USA) at a label/protein ratio of 2:1 [14] Avidin-peroxidase, sugars, and chemical reagents were from (Sigma Chemical Co, St. Louis, MO, USA), 3-amino-9-ethyl-carbazole (AEC) kit used as substrate for peroxidase was obtained from Vector Laboratories. Biotin-labeled mouse anti-galectin-3 was obtained from Invitrogen (Carlsbad, CA USA).
Source of tissues
Ten paraffin-embedded blocks from breast tissues diagnosed with fibroadenoma were kindly donated by Paulina Leyva, from the Pathology Department of the School of Medicine, UABJO, Oaxaca, Mexico. Ten healthy control tissue samples were obtained from cosmetic procedures at the Plastic Surgery service from the Mexican Institute of Social Security (IMSS, for its initials in Spanish), Mexico.
Ethical approval
The study protocol was approved by the Institutional Review Board of Research of the Medical School of UABJO.
Immunohistochemistry
Paraffin-embedded blocks from fibroadenoma and normal breast tissues, the latter used as controls, were cut in 6-μm-thick sections. Sections were incubated with each biotin-labeled lectin (1 μg/ml) or monoclonal anti-galectin-3 antibody (dilution 1:100), overnight at 4°C. After incubation, the slides were washed with PBS, pH 7.4, and covered with 300 μl of 5% skimmed milk in PBS, pH 7.4, and incubated for 12 h at 4°C. Then, after washing with PBS, pH 7.4, the samples were labeled with streptavidin-peroxidase (1:1000 in PBS) for 1 h at 37°C. Unbound conjugate was removed by washing six times with PBS. The binding of lectins or antibody was revealed by incubating with 3-amino-9-ethyl-carbazole (AEC), following instructions of manufacturer (Invitrogen), during 15 min at 37°C. The reaction was stopped by washing with water. Slides were observed with an AXIOSCOP 40 microscope (Zeiss, Germany) equipped with a digital camera AXIOCAM MRC (Zeiss) and micrographs were analyzed with the AXIOVISION 4.3 Software (Zeiss).
Immunofluorescence
Double labeling of slides was performed as follows: Tissue samples were labeled with lectins (1 μg/ml) overnight at 4°C and monoclonal anti-galectin-3 antibody used at 1:100 following the same procedure as previously described, except that lectin binding was indirectly recognized with extravidin-FITC conjugated (Sigma Chemical Co.) and visualized using a green filter. Anti-galectin antibodies were revealed with extravidin-red-X conjugate (Invitrogen) and visualized using a red filter. Slides were observed with an AXIOSCOP 40 microscope (Zeiss), equipped with a digital camera AXIOCAM MRC (Zeiss) and micrographs were analyzed with the AXIOVISION 4.3 Software (Zeiss).
Lectin specificity
To determinate the lectins’ specificity in control breast epithelium and fibroadenomas, lectin histochemistry and immunoflourescence assays were performed using lectins incubated with 200 mM of their specific monosaccharide (N-acetyl-D-galactosamine) 30 min before use.
Statistical analysis
Fisher’s exact test using Woolf’s approximation was performed using GraphPad InStat version 3.00, GraphPad Software, San Diego California USA.
Results
Lectins and anti galectin-3 histochemistry
Numbers of samples positive and negative to either lectins or antibody are summarized in Table Table1.1. As indicated in Table Table2,2, in control samples, obtained from healthy tissues. Amaranthus leucocarpus lectin (ALL) recognized ducts in healthy breast samples (Figure (Figure1.1. A1); whereas, in fibroadenoma tissues, this lectin recognized ducts and stroma cells (Figure (Figure1.1. A2). A. integrifolia lectin recognized ducts in healthy (Figure (Figure1.1. B1) and fibroadenoma samples equally well (Figure (Figure1.1. B2). A. hypogaea recognized ducts in healthy (Figure (Figure1.1. C1) and fibroadenoma samples (Figure (Figure1.1. C2). Anti-galectin-3 antibody showed a weak staining in ducts of healthy samples (Figure (Figure1.1. D1); however, in fibroadenoma tissue, the antibody recognized ducts and stroma cells (Figure (Figure1.1. D2).
Table 1
Table 1
Interaction of lectin or antibodies with all the healthy and fibroadenoma breast samples* used in this study
Table 2
Table 2
Staining of normal and fibroadenoma using anti-galectin-3 antibody and lectins*
Figure 1
Figure 1
Lectin and anti-galectin-3 histochemistry in healthy breast and fibroadenoma samples. Amaranthus leucocarpus recognizes ducts in healthy breast samples (A1): in fibroadenoma, Amaranthus leucocarpus lectin recognizes ducts and stroma cells (A2). Artocarpus (more ...)
Immunofluorescence
Lectins and anti-galectin-3, in double labeling immunoflourescence, in healthy breast and fibroadenoma samples, showed weak staining with anti-galectin-3 in healthy samples (Figure (Figure2.2. A). A. integrifolia lectin recognized ducts and stroma in healthy (Figure (Figure2.2. B1) and in fibroadenoma samples; whereas antigalectin-3 recognized ducts and stroma (Figure (Figure2.2. B2). A. hypogaea recognized ducts and stroma in healthy samples (Figure (Figure2.2. C1); whereas, in fibroadenoma samples, anti-galectin-3 recognized ducts and stroma (Figure (Figure2.2. C2). Amaranthus leucocarpus recognized ducts and stroma in healthy breast samples (Figure (Figure2.2. D1); in fibroadenoma samples, anti-galectin-3 recognized ducts and stroma (Figure (Figure2.2. D2). A. integrifolia lectin recognized luminal cells of ducts in fibroadenoma (Figure (Figure3.3. A1). No interaction with luminal cells was observed in fibroadenomas using anti-galectin-3 antibody (Figure (Figure3.3. A2). Lectins and anti-galectin-3 antibody staining showed no co-localization.
Figure 2
Figure 2
Lectin and anti-galectin-3 double labeling histochemistry, in healthy breast and fibroadenoma samples. Weak staining with anti-galectin-3 was observed in healthy samples (A). Artocarpus integrifolia lectin recognizes ducts and stroma in healthy breast (more ...)
Figure 3
Figure 3
Lectin and anti-galectin-3 double labeling histochemistry in fibroadenoma samples.Artocarpus integrifolia lectin recognizes luminal cells of ducts (A1). No interaction with luminal cells was observed in fibroadenoma using anti-galectin-3 (A2). White arrow (more ...)
Statistical results
Lectins and using anti-galectin-3 antibody were not statistically significant
Discussion
A fibroadenoma is a benign tumor with stromal and epithelial elements [15,16]; however, it has been associated with increased risk for breast cancer, particularly when associated with fibrocystic changes, proliferative breast disease, or a family history of breast cancer [17]. Recently, studies in alterations of the membrane’s protein glycosylation have been performed to understand better the changes taking place during cellular transformation to cancer [18,19]. Lectins, due to their higher specificity for carbohydrates and glycoconjugates, have been used to detect glycosylation changes in cancer cells [20-22]. In this work, we studied the glycosylation pattern in fibroadenomas using lectins with specificity for N-acetyl-D-galactosamine linked to protein or lipids. In fibroadenoma samples, lectins recognized different cytoplasmic regions from those recognized by antibodies, indicating that some cells express mucin-type O-glycans. In dermal carcinoma, as well as in carcinoma in situ[23], Arachis hypogaea, Artocarpus integrifolia, and Amaranthus leucocarpus lectins recognize the Galβ1-3GalNAc or TF antigen (Thomsen-Friedenreich antigen). Our results showed that the A. leucocarpus lectin recognized ducts in control samples; whereas, in fibroadenoma, it recognized ducts and some stromal cells. The recognition pattern of Arachis hypogaea was the same in control and fibroadenoma tissues, i.e., the lectin recognized ducts. A. intergrifolia recognized ducts in control samples, but in fibroadenoma the lectin recognized luminal cells. The ability of lectins to bind carbohydrates depends on their 3-D structure [24,25] and on their capacity to detect subtle variations in the conformation of carbohydrate structures of cell surfaces [25]. This ability could be explained by the variability in the size of the carbohydrate-recognition domain (CDR) and the variability in quaternary association [25]. Interestingly, the CDR of A. leucocarpus lectin recognizes GalNAc residues when they are spaced out in glycan structures, whereas GalNAc residues arranged in clusters prevent interaction with the lectin [26]. These glycans have been related with cervical cancer development [27] and are present in fibroadenomas [28], whereas Artocarpus integrifolia lectin can recognize clusters of TF antigen.
Galectin-3 is a naturally occurring galactoside-binding lectin expressed intra- and extra-cellularly by many cell types [29]. It has been shown that galectin-3 expression is increased in patients with breast, gastrointestinal, or lung cancer [30]. Moreover, higher galectin-3 expression has been shown in patients with metastatic disease than in patients with localized tumors [31]. Cytoplasmic galectin-3 is known to be anti-apoptotic, whereas nuclear galectin-3 promotes pre-mRNA splicing [32]. Cell surface galectin-3 is involved in various cell-cell and cell-matrix interactions [33,34] and enhances cancer cell adhesion and invasion through basement membrane by interacting with extracellular matrix proteins such as fibronectin, collagen, or laminin [35,36]. Galectin-3 expressed on the endothelial cell surface has been shown to promote adhesion of breast cancer cells to the endothelium by interaction with cancer- associated Thomsen-Friedenreich antigen cell surface molecules [37,38]. TF antigen is the core I structure of mucin-type O-linked glycans, but in its simplest nonsialylated form, as non-extended form it acts as an oncofetal antigen, and its presence/expression is increased in malignant and premalignant epithelia [39,40]. A weak interaction with ducts, in healthy samples was observed when anti-galectin-3 antibody was used, whereas, in fibroadenoma samples, the interaction was observed in ducts and stromal cells.
Conclusions
Our results suggest that galectin-3 and Galß1,3-GalNAC glycosylated glycoproteins represent important elements in fibroadenomas’ development, reinforcing the notion that lectins constitute a very useful tool for the study of breast cancer.
Abbreviations
AEC: 3-amino-9-ethyl-carbazole; CDR: Carbohydrate-recognition domain; FITC: Fluorescein isothiocyanate; Gal: Galactose; GalNAc: N-acetylgalactosamine; PBS: Phosphate buffered saline; Ser: Serine; Thr: Threonine; TF: Thomsen-Friedenreich antigen; UABJO: Universidad Autónoma “Benito Juárez” de Oaxaca; UNAM: Universidad Autónoma de México; USA: United Satates of America.
Competing interests
The authors declare that they have no competing interest
Authors’ contributions
IBG processed the samples, analyzed data, and reviewed the literature. EP analyzed data and reviewed the manuscript. PH performed literature review, drafted most of the manuscript. EZ analyzed data and reviewed the manuscript. SA, MM, MAM and LP reviewed the manuscript. All authors have read and approved the final manuscript.
Acknowledgements
This work was supported by PTC-FMC-14 and Programa de Fortalecimoento de Cuerpos Academicos 2011 UABJO-CA-043. We are especially grateful to Paulina del Carmen Leyva Bohorquez (Pathology Laboratory of the Mexican Institute of Social Security, Oaxaca, Mexico) and Claudia Hernandez Valverde of the Plastic Surgery service of the Mexican Institute of Social Security, for technical assistance.
  • Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, Tos AP, Fortunati N, Catalano MG, Bussolati G. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol. 2006;19:599–606. doi: 10.1038/modpathol.3800574. [PubMed] [Cross Ref]
  • Kuijper A, Buerger H, Simon R, Schaefer KL, Croonen A, Boecker W, Van der Wall E, Van Diest PJ. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002;197:575–581. doi: 10.1002/path.1161. [PubMed] [Cross Ref]
  • Dixon JM. Cystic disease and fibroadenoma of the breast: natural history and relation to breast cancer risk. Br Med Bull. 1991;47:258–271. [PubMed]
  • Martin PM, Kuttenn F, Serment H, Mauvais-Jarvis P. Studies on clinical, hormonal and pathological correlations in breast fibroadenomas. J Steroid Biochem. 1978;912:1251–1255. [PubMed]
  • Bulmer JC. Lectin hystochemistry of pregnant rat uterine tissues. J Anat. 1996;188:197–205. [PubMed]
  • Tanda N, Mori S, Nose M, Saito T, Song ST, Sato A. Expression of Phaseolus vulgaris leukoagglutinin-binding oligosaccharides in oral squamous cell carcinoma: possible association with the metastatic potential. Pathol Int. 1996;46:639–645. doi: 10.1111/j.1440-1827.1996.tb03666.x. [PubMed] [Cross Ref]
  • Eckart L, Haleh N. Lectin histochemistry of the resected adenocarcinoma of the lung, Helix pomatia agglutinin binding is an independent prognostic factor. Am J Pathol. 2002;160:1001–1008. doi: 10.1016/S0002-9440(10)64921-8. [PubMed] [Cross Ref]
  • Kamura V, Shanthi P, Madhavan M. Lectin binding patterns in benign and malignant lesions of the breast. Indian J Pathol Microbiol. 1992;35:289–297. [PubMed]
  • Yamashita Y, Chung YS, Horie R, Kanagi R, Sowa M. Alterations in gastric mucin with malignant transformation: novel pathway for mucin synthesis. J Natl Cancer Inst. 1995;87:441–446. doi: 10.1093/jnci/87.6.441. [PubMed] [Cross Ref]
  • Shuman J, Dongxu Q, Koganty R, Longenecker R, Campbell P. Glycosylation versus conformational preferences of cancer associated mucin core. Glyconconj J. 2000;17:835–848. doi: 10.1023/A:1010909011496. [PubMed] [Cross Ref]
  • Gorocica P, Lascurain R, Hemandez P, Porras F, Bouquelet S, Vazquez L, Zenteno E. Isolation of the receptor for Amaranthus leucocarpus lectin from murine peritoneal macrophages. Glycoconj J. 1998;8:809–814. [PubMed]
  • Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2004;19:543–548. [PubMed]
  • Zenteno E, Ochoa JL. Isolation and characterization of Amaranthus leucocarpus lectin. Phytochemistry. 1983;27:313–317.
  • Savage D, Mattson G, Desai S, Nielander G, Morgensen S, Coklin E. Avidin-biotin chemistry: a handbook. Rockford, IL: Pierce Chemical Co; 1992. pp. 1–50.
  • Brentani MM, Pacheco MM, Oshima CT. Steroid receptors in breast angiosarcoma. Cancer. 1983;51:2105–2111. doi: 10.1002/1097-0142(19830601)51:11<2105::AID-CNCR2820511125>3.0.CO;2-1. [PubMed] [Cross Ref]
  • De Luca LA, Traiman P, Bacchi CE. An unusual case of malignant cystosarcoma phyllodes of the breast. Gynecol Oncol. 1986;24:91–96. doi: 10.1016/0090-8258(86)90011-9. [PubMed] [Cross Ref]
  • Dupont WD, Page DL, Parl FF. Long term risk of breast cancer in women with fibroadenoma. N Eng J Med. 1994;331:10–15. doi: 10.1056/NEJM199407073310103. [PubMed] [Cross Ref]
  • Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of Sialyl Lewisa as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer. 1995;75:2051–2056. doi: 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4. [PubMed] [Cross Ref]
  • Rajpert-De Meyts E, Poll SN, Goukasian I, Jeanneau C, Herlihy AS, Bennett EP, Skakkebaek NE, Clausen H, Giwercman A, Mandel U. Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation. Virchows Arch. 2007;4:805–814. [PubMed]
  • Goldstein IJ, Hughes RC, Monsigny M, Osawa T, Sharon N. What should be called a lectin? Nature. 1980;28:286.
  • Lis H, Sharon N. Lectins as molecules and as tools. Ann Rev Biochem. 1986;55:35–67. doi: 10.1146/annurev.bi.55.070186.000343. [PubMed] [Cross Ref]
  • Karuna V, Shanthi P, Madhavan M. Lectin binding patterns in benign and malignant lesions of the breast. Indian J Pathol Microbiol. 1992;4:289–297. [PubMed]
  • Cui Y, Noguchi H, Kiguchi K, Aoki D, Susumu N, Nozawa S, Kawakami H, Hirano H, Iwamori M. Human cervical epidermal carcinoma-associated intracellular localization of glycosphingolipid with blood group A type 3 chain. Jpn J Cancer Res. 1993;84:664–672. doi: 10.1111/j.1349-7006.1993.tb02027.x. [PubMed] [Cross Ref]
  • Weiss IW, Drickramer K. Structural basis of the lectin-carbohydrate recognition. Annu Rev Biochem. 1996;65:441–473. doi: 10.1146/annurev.bi.65.070196.002301. [PubMed] [Cross Ref]
  • Sharma V, Surolia A. Analysis of carbohydrate recognition by legume lectin: size of the combining site loops and their primary specificity. J Mol Biol. 1997;267:433–445. doi: 10.1006/jmbi.1996.0863. [PubMed] [Cross Ref]
  • Hernández P, Tetaert D, Vergoten G, Debray H, Jimenez MC, Fernández G, Agundis C, Degand P, Zenteno E. Specificity of Amaranthus leucocarpus syn hypocondriacus lectin for O-glycopeptides. Biochim Biophys Acta. 2004;1674:282–290. doi: 10.1016/j.bbagen.2004.07.008. [PubMed] [Cross Ref]
  • Santaella A, Gallegos B, Perez E, Zenteno E, Hernández P. Use of Amaranthus leucocarpus lectin to differentiate cervical dysplasia (CIN) Prep Biochem Biotechnol. 2007;37:219–228. doi: 10.1080/10826060701386703. [PubMed] [Cross Ref]
  • Gallegos B, Pérez-Campos E, Martinez R, Leyva P, Martinez M, Hernández R, Pina S, Hernández C, Zenteno E, Hernández P. O-glycosylation expression in fibroadenoma. Prep Biochem Biotechnol. 2010;40:1–12. [PubMed]
  • Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Cancer. 2005;5:29–41. [PubMed]
  • Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res. 2000;6:1389–1393. [PubMed]
  • Yang RY, Hsu DK, Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA. 1996;93:6737–6742. doi: 10.1073/pnas.93.13.6737. [PubMed] [Cross Ref]
  • Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA. 1995;92:1213–1217. doi: 10.1073/pnas.92.4.1213. [PubMed] [Cross Ref]
  • Hughes RC. Galectins as modulators of cell adhesion. Biochimie (Paris) 2001;83:667–676. [PubMed]
  • Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, Iacobelli S. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 2002;23:313–320. doi: 10.1016/S1471-4906(02)02232-9. [PubMed] [Cross Ref]
  • Ochieng J, Platt D, Tait L, Hogan V, Raz T, Carmi P, Raz A. Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry. 1993;32:4455–4460. doi: 10.1021/bi00067a038. [PubMed] [Cross Ref]
  • Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj. 2004;19:543–549. [PubMed]
  • Glinsky VV, Glinsky GV, Glinskii OV, Huxley VH, Turk JR, Mossine VV, Deutscher SL, Pienta KJ, Quinn TP. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003;63:3805–3811. [PubMed]
  • Zou J, Glinsky VV, Landon LA, Matthews L, Deutscher SL. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis. 2005;6:309–318. [PubMed]
  • Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on beta-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res. 2000;60:2584–2588. [PubMed]
  • Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 2001;61:4851–4857. [PubMed]
Articles from BMC Research Notes are provided here courtesy of
BioMed Central